A Phase III Multicenter Randomized Open Label Study Comparing Atezolizumab Anti PD L1 Antibody
Research payments
$3,243,179
Through program year 2025, $3,243,179 in research payments was reported against A Phase III Multicenter Randomized Open Label Study Comparing Atezolizumab Anti PD L1 Antibody, across 711 payments.
- Paid by (largest first)
- Roche Products Limited; Hoffmann-La Roche Limited; Genentech, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $175,820 | 18 |
| 2024 | Research | $286,091 | 46 |
| 2023 | Research | $308,152 | 134 |
| 2022 | Research | $560,301 | 102 |
| 2021 | Research | $649,887 | 143 |
| 2020 | Research | $511,794 | 158 |
| 2019 | Research | $751,135 | 110 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
5 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.